Analytical Procedure Lifecycle Approaches in Accordance with ICH Q14 and ICH Q2(R2): Opportunity Knocks, or Just Another Challenge and Headache? Part 1

The pharmaceutical industry is undergoing a significant transformation in the way analytical procedures are developed, validated, and maintained. This shift is largely driven by the progressive adoption of quality by design (QbD) principles, which emphasize a lifecycle and risk-based approach to ensure the quality of pharmaceutical products and the reliability and robustness of their associated analytical procedures. Over the past two decades, the International Council for Harmonisation (ICH) has developed a series of guidelines (Q8–Q12) to support this evolution, culminating most recently in the release of ICH Q14¹ and the revision of ICH Q2(R2),² both officially adopted in November 2023. Complementing this global regulatory momentum, in 2020 the United States Pharmacopeia (USP) introduced General Chapter <1220>,³ Analytical Procedure Lifecycle, which marks a paradigm shift from traditional validation practices to a science- and risk-based framework that emphasizes the concept of fitness for purpose. This framework introduces key concepts such as the analytical target profile (ATP) and encompasses three interrelated stages: procedure design (Stage 1), procedure performance qualification (Stage 2), and ongoing procedure performance verification (Stage 3), as illustrated in Figure 1. The TP defines the intended purpose of the analytical procedure and the performance requirements for measuring product quality attribute(s), guiding all three lifecycle stages and ensuring the method remains fit for its intended use.^1-5 In this way, the ATP serves as the foundation of the analytical method within the overall product control strategy,^3-11 supporting flexibility in method and technology selection. At the core of the lifecycle is the integration of prior knowledge, risk assessment, and performance-based criteria, all of which align closely with QbD principles maximizing knowledge about procedure performance, allowing for greater flexibility and regulatory transparency. This clearly demonstrates that the analytical procedure lifecycle approach is fundamentally driven by analytical QbD (AQbD) principles, with quality risk management playing a central role.

In the same context, ICH Q14 provides a structured, QbD-based enhanced approach for analytical procedure development, while ICH Q2(R2) expands the scope of procedure validation to include a broader array of analytical procedures — including bioassays, multivariate models, and those used for stability and release testing. Both emphasize the role of prior knowledge, platform methods, and knowledge management to support efficient, modular strategies and continuous improvement. Building off existing ICH guidelines (Q8-Q12) and along with USP chapter <1220>, the newly revised USP <1225>¹² Validation of Analytical Procedures, published in the USP PF 51⁶ on SeptemberNovember 1^st, 2025), and new USP chapter <1221>¹³ on Ongoing Procedure Performance Verification (OPPV, published in the USP PF 51⁴ on July 1^st, 2025), ICH Q14 and Q2(R2) guidelines integrate analytical procedures into the pharmaceutical quality system and redefine expectations across development, validation, and post-approval stages.

It is worth noting that, since these guideline’s official adoption in November 2023, regulatory agencies such as European Medicines Agency, U.S. Food and Drug Administration, Swissmedic, Health Canada, Japan’s Pharmaceuticals and Medical Devices Agency, have started implementing them, reflecting a global commitment to advancing analytical science through life ycle and risk-based approaches. While the enhanced AQbD-based approach for analytical procedures is not mandatory, its adoption can facilitate more agile and risk-proportionate regulatory strategies. The implementation of risk assessment tools (including systematic approaches for knowledge gain) enables the design of proven acceptable ranges and method operable design regions, which can be leveraged as part of post-approval change management protocols, helping minimize regulatory burden and support continuous improvement across the procedure lifecycle. Although ICH Q14 and ICH Q2(R2) are consistent with the principles described in USP <1220>, they are not in full agreement, highlighting the need for continued harmonization efforts. Collectively, these developments have been instrumental in driving a quality paradigm shift across the pharmaceutical industry, encouraging science- and risk-based decision-making, lifecycle management, and continuous improvement in analytical procedure development and validation.

With the recent introduction of ICH Q14 and the revised ICH Q2(R2) guidelines and several updated pharmacopeial chapters, what are the key emerging aspects, and primary opportunities?

These guidelines emphasize an integrated lifecycle approach, guided by AQbD principles, to manage analytical procedures. This approach generates additional knowledge to support a holistic, risk-based product control strategy, an essential component of regulatory submission dossiers. AQbD is not an entirely new concept. Commonly used risk assessment tools such as design of experiments and predictive modelling have been applied in the pharmaceutical industry for many years to support method development, though the extent of their adoption varies depending on factors such as organizational culture and maturity, company size, and available resources. In this context, the use of these tools has often been limited and not fully leveraged to enhance risk assessment activities during procedure design or to document the science-based decision-making process that leads to the selection of final analytical procedures and control strategies. As a result, the knowledge generated during procedure design (i.e. method development) is often poorly captured and difficult to trace when further investigation or risk assessment is needed, for example, when changes to analytical conditions are required. This highlights opportunities for improvement in building a strong knowledge foundation during the design phase to support subsequent stages such as validation, transfer, and ongoing verification. Addressing this gap is one of the key objectives of ICH Q14. What emerges as a key concept is to initiate method development (procedure design) with a clear end goal in mind: ensuring fitness for purpose, rather than deferring this responsibility to scientists conducting validation activities after Stage 1, which should serve only to confirm validity, and should not serve as the primary activity to build quality into the procedure. To achieve this, robustness assessment and the design of method conditions should be driven by knowledge acquired on potential sources of variability during procedure (method) development. In other words, the objective is not merely to define an "optimized" method, but to understand the analytical factors, and their potential interactions, that could lead to method failure, and to use that understanding to design robust, fit-for-purpose conditions. In this context, ICH Q14 introduced the concepts of minimal and enhanced approaches to analytical procedure development, with the key difference being the level of risk assessment and scientific understanding applied.

Equally important is the establishment of performance requirements typically derived from product specifications, which strengthens the capability of procedure design to identify risks early, before proceeding to validation (Stage 2). This is where the analytical target profile (ATP), as described in ICH Q14 and USP <1220>, becomes instrumental. It provides a structured framework to establish an end-goal mindset by translating the concept of “fitness for purpose” into clear performance requirements. The ATP serves as a unifying element across all stages of the analytical lifecycle, ensuring that fitness for purpose is consistently maintained throughout. Similarly, ICH Q2(R2) offers clarification and introduces alternative approaches to support the estimation of measurement uncertainty during validation, whether by considering bias and precision together or independently. However, the guideline stops short of explicitly linking these estimations to the primary performance requirements defined in the ATP and simply refers to it as “acceptance criteria.” ICH Q2(R2) embeds validation within a lifecycle framework, aligned with the three-stage model described in USP <1220>. ICH Q2(R2) also expands the scope of validation to include non-chromatographic methods, multivariate calibration models, and bioassays. It introduces the concept of “reportable range” in place of “linearity,” and incorporates statistical tools such as residual plots and prediction intervals to assess accuracy and precision. ICH Q14 promotes the use of prior knowledge and platform analytical methods to streamline development, especially in complex product classes like biological, RNA, and vaccine-based products. In the same line as Q14, Q2(R2) also supports leveraging prior knowledge (e.g., from development data, previous products, etc.). By leveraging validated experience from similar molecules or procedures, and linking them to ATP criteria, organizations can benefit and avoid redundant validation efforts and enhance cross-product consistency. This strategy supports faster development timelines, efficient tech transfer, and reduced regulatory burden without compromising scientific rigor.

Ongoing performance monitoring and continuous improvement are another two important areas outlined in ICH Q14 and USP <1220>. AQbD encourages a lifecycle mindset that extends into routine use and long-term monitoring. Embedding tools such as control charts, trend analysis, and periodic performance reviews allow early detection of shifts in procedure performance. This proactive approach supports continuous improvement, helps maintain alignment with ATP expectations, and ensures consistent analytical reliability throughout the product’s lifecycle. While ICH Q14 acknowledges the importance of ongoing monitoring, it offers limited guidance on its implementation. Further direction can be found in recent publications,^9-11,14,15 and the newly proposed USP draft chapter <1221>¹³

ICH Q14 provides a foundation for regulatory flexibility and post-approval changes by introducing a solid foundation for post-approval change management protocols, helping organizations manage changes to analytical procedures efficiently and predictably (e.g. shifts in technology or materials). The ATP remains central as a technology-independent performance benchmark. It also facilitates modernization by enabling the adoption of new technologies without sacrificing method performance. Chapter 7 of ICH Q14 outlines a decision tree that helps categorize certain changes into lower reporting tiers, such as “notification low,” thus minimizing regulatory burden. Leveraging the enhanced approach during ATP development increases the likelihood of qualifying for these streamlined categories and aligns with ICH Q12’s¹⁶ lifecycle management framework.

In summary, the primary opportunity lies in the availability of a more systematic and structured framework to support strategic risk assessment, with a clear goal: to maximize understanding of sources of variability and performance risks during procedure design (method development), enabling the development of more effective control strategies. Additional guidance documents are expected to follow, helping to address remaining gaps.

Why is the ATP considered a central element in the analytical procedure lifecycle as described in ICH Q14?

The ATP is a key element of the analytical procedure lifecycle introduced in ICH Q14 and previously discussed in USP <1220>³. It forms the foundation of the lifecycle approach by clearly defining the intended purpose and performance requirements directly linking to product critical quality attributes (CQAs). In this sense, the ATP is a game changer, shifting the focus from checking boxes to ensuring fitness for purpose throughout the procedure lifecycle. By establishing performance criteria (typically derived from products specification), such as maximum acceptable measurement uncertainty, the ATP integrates data quality into the lifecycle framework and supports the generation of reliable reportable values. Figure 2 illustrates a simplified view of the ATP's role in setting fitness-for-purpose criteria across the lifecycle, guiding method selection, validation, and change management. This performance-based approach also supports regulatory flexibility through justification aligned with analytical risk. The ATP is technology-independent and applicable across modalities and development stages. It enables the use of alternative technologies when appropriate, thus promoting innovation while maintaining procedure suitability. It is central to lifecycle control and risk-based decision-making. Tailored strategies for estimating measurement uncertainty may be applied based on prior knowledge and the product’s development stage (e.g., prediction intervals during validation), helping to strengthen confidence in results and support informed decisions. Importantly, the ATP is a living document that evolves as product and process understanding increases.¹⁷ For example, a CQA such as "related substances" may need revision due to changes in the synthetic route or new knowledge of degradation pathways. Any such modification may require adaptation or redevelopment of the associated analytical procedure, followed by reassessment to ensure continued suitability.

The next articles in this series will address other key topics, such as: What are the key opportunities associated with adopting risk-based approaches within the context of the lifecycle procedure? What are the main barriers and challenges to the implementation of AQbD principles? Could the perceived framework introduced in ICH Q14 complexity discourage the industry from fully implementing it? Is it necessary to adopt the full framework all at once to benefit from the enhanced approach? Are there concerns around how regulators will interpret and apply Q2(R2) and Q14?

References

1. ICH Guideline Q14 Analytical Procedure Development, 2023
2. ICH Guideline Q2(R2) Validation of Analytical Procedures, 2023
3. USP General Chapter <1220> Analytical Procedure Lifecycle, 2022.
4. Borman, P.; Campa, C.; Delpierreet, G. et al. Selection of Analytical Technology and Development of Analytical Procedures Using the Analytical Target Profile. Anal Chem 2022, 94 (2), 559–570. DOI: 10.1021/acs.analchem.1c03854
5. Jackson, P.; Borman, P.; Campa, C. et al. Using the Analytical Target Profile to Drive the Analytical Method Lifecycle. Anal Chem 2019, 91 (4), 2577–2585. DOI: 10.1021/acs.analchem.8b04596
6. Barnett, K.; Chestnu, S.; Clayton, N. et al. Defining the Analytical Target Profile. Pharm. Eng. 2018. https://ispe.org/pharmaceutical-engineering/march-april-2018/defining-analytical-target-profile
7. Schweitzer, M.; Pohl, M.; Hanna-Brown, M. et al. Implications and Opportunities of Applying QbD Principles to Analytical Measurements, Pharm. Tech. 2010, 34 (2). https://www.pharmtech.com/view/implications-and-opportunities-applying-qbd-principles-analytical-measurements-0
8. Barnett, K. L.; McGregor, P. L.; Martin, G. P. et al. Analytical Target Profile: Structure and Application Throughout the Analytical Lifecycle, USP Stimuli Article. Pharm. Forum 2016, 42 (5).
9. Rignall, A.; Borman, P.; Hanna-Brown, M. et al. Analytical Procedure Lifecycle Management: Current Status and Opportunities. Pharm. Tech. 2018, 42, 18–23. https://www.pharmtech.com/view/analytical-procedure-lifecycle-management-current-status-and-opportunities
10. Guiraldelli, A. M.; Lourenço, F. R.; Borman, P. et al. Analytical Target Profile (ATP) and Method Operable Design Region (MODR), in: Introduction to Quality by Design in Pharmaceutical Manufacturing and Analytical Development. AAPS Introductions in the Pharmaceutical Sciences; M.C. Breitkreitz, H.C. Goicoechea, Eds. Springer, 2023; pp. 199–219.
11. Guiraldelli, A. M.; Lourenço, F. R.; Borman, P. et al. Analytical Quality by Design Fundamentals and Compendial and Regulatory Perspectives, in: Introduction to Quality by Design in Pharmaceutical Manufacturing and Analytical Development. AAPS Introductions in the Pharmaceutical Sciences; M.C. Breitkreitz, H.C. Goicoechea, Eds. Springer, 2023; pp. 163–198.
12. USP General Chapter <1225> Validation of Analytical Procedures (draft), Pharmacopeial Forum, USP PF 51(6) (2025)
13. USP General Chapter <1221> Ongoing Procedure Performance Verification (draft), Pharmacopeial Forum, USP PF 51(4) (2025).
14. Borman, P. J.; Guiraldelli, A. M.; Weitzel, J. et al. Ongoing Analytical Procedure Performance Verification Using a Risk-Based Approach to Determine Performance Monitoring Requirements. Anal Chem. 2024, 96, 966–979. DOI: 10.1021/acs.analchem.3c03708
15. Borman, P.; Guiraldelli, A.; Weitzel, J. et al. Ongoing Analytical Procedure Performance Verification - Stage 3 of USP <1220>. Pharm. Tech. 2023, 47 (3), 40–44. https://www.pharmtech.com/view/ongoing-analytical-procedure-performance-verification-stage-3-of-usp-1220-
16. ICH Guideline Q12 Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management, 2019
17. Best Practices for the Development, Validation and Registration of Analytical Procedures-Implementation of ICH Q2 (R2) and Q14 for Biologics. BioPhorum website 2025. https://www.gmp-compliance.org/gmp-news/biophorum-publishes-guidance-for-ich-q2r2-and-q14-implementation (accessed July 14, 2025).
18. ICH Guideline Q9 Quality Risk Management, 2005.

Download the PDF Here